A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)
Pai, V., Paneerselvam, A., Mukhopadhyay, S., Bhansali, A., Kamath, D., Shankar, V., Gambhire, D., Jani, R. H., Joshi, S., Patel, P.Volume:
8
Language:
english
Journal:
Journal of Diabetes Science and Technology
DOI:
10.1177/1932296813518680
Date:
January, 2014
File:
PDF, 374 KB
english, 2014